The Company’s research and development expenses were comprised of the following (thousands):

Schedule of Research and Development Expenses 

Costs incurred pursuant to the Amarex agreements were as follows (thousands):

Costs incurred pursuant to the Jubilant agreements were as follows (thousands):

Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):

Costs incurred pursuant to the Erasmus agreements were as follows (thousands):

Costs incurred pursuant to the Azenova agreements were as follows (thousands):

Costs incurred pursuant to the Alcami agreements were as follows (thousands):